AMC
ITCI

Asset Management Corp’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Asset Management Corp’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-19,185
Closed -$783K – 207
2021
Q2 		$783K Sell
19,185
-2,500
-12% -$92.4K 0.45% 56
2021
Q1 		$736 Buy
21,685
+5,300
+32% +$184K 0.32% 64
2020
Q4 		$553K Sell
16,385
-4,300
-21% -$113K 0.31% 84
2020
Q3 		$531K Buy
20,685
+2,750
+15% +$62.7K 0.32% 73
2020
Q2 		$460K Hold
17,935
– – 0.29% 69
2020
Q1 		$276K Buy
17,935
+805
+5% +$17.5K 0.25% 89
2019
Q4 		$588K Buy
+17,130
New +$206K 0.42% 67

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Asset Management Corp's ITCI Position: Q3 2021 in Review

Asset Management Corp sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2021, closing a stake of 19,185 shares — an estimated $783K sold.

Asset Management Corp first reported a position in ITCI in Q4 2019 and held it in 7 quarters. The position peaked at $783K in Q2 2021. 180 funds tracked by Wall St. Rank hold ITCI as of Q3 2021.

  • Asset Management Corp reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2021 after selling out during the quarter.
  • Asset Management Corp sold 19,185 Intra-Cellular Therapies Inc. shares in Q3 2021, an estimated $783K.
  • Asset Management Corp first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 7 quarters.
  • Asset Management Corp's Intra-Cellular Therapies Inc. position peaked at $783K in Q2 2021.
  • 180 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2021.

Based on Asset Management Corp's 13F filing for Q3 2021, filed 13 Oct 2021.